PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Both companies show declining cash positions (-26.68% vs AGEN's -23.37%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Cash + STI yoy 1.25-1.5x AGEN's -23.37%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Above 1.5x AGEN's -22.78%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-27.05%
1.25-1.5x AGEN's -22.85%. Bruce Berkowitz checks if strong current asset growth is used effectively.
-7.44%
Below half AGEN's 1.89%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AGEN and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Above 1.5x AGEN's 6.92%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-5.69%
≥ 1.5x AGEN's -0.22%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
≥ 1.5x AGEN's -15.43%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
9.15%
Less than half of AGEN's -13.79%. David Dodd sees a more disciplined AP approach or lower volume.
-74.86%
Less than half of AGEN's 1.23%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Below half of AGEN's 15.88%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Similar yoy to AGEN's 9.21%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
Less than half of AGEN's 0.06%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.31%
1.25-1.5x AGEN's 3.08%. Martin Whitman is wary of bigger liability expansions.
1.65%
Above 1.5x AGEN's 0.07%. Michael Burry suspects heavy new equity expansion or dilution.
-3.34%
0.75-0.9x AGEN's -3.76%. Bill Ackman questions if competitor reinvests profits more robustly.
-6.51%
Less than half of AGEN's -18.81%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
1.25-1.5x AGEN's -27.00%. Bruce Berkowitz notes an above-average equity expansion.
-25.21%
≥ 1.5x AGEN's -15.43%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
Both AGEN and the company show zero Total Investments Growth.
-11.75%
Less than half of AGEN's 5.38%. David Dodd sees less overall debt expansion vs. competitor.
27.85%
Similar yoy changes to AGEN's 29.78%. Walter Schloss sees parallel net leverage strategies.